137 related articles for article (PubMed ID: 7956716)
1. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
2. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Oostendorp-van de Ruit M; Van der Pluijm G; Löwik CW; Papapoulos SE
J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
5. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
6. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
8. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Paget's bone disease with the bisphosphonate APD.
Mautalen CA
Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243
[No Abstract] [Full Text] [Related]
10. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
12. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
13. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
Cantrill JA; Buckler HM; Anderson DC
Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
[TBL] [Abstract][Full Text] [Related]
14. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
[TBL] [Abstract][Full Text] [Related]
16. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
17. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate space measurement in Paget's disease of bone treated with APD.
Stone MD; Marshall DH; Hosking DJ; Perkins AC; Evans AJ; Wastie ML
J Bone Miner Res; 1992 Mar; 7(3):295-301. PubMed ID: 1316715
[TBL] [Abstract][Full Text] [Related]
19. [A single infusion of Pamidronate (APD) in Paget's disease of bone].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157
[TBL] [Abstract][Full Text] [Related]
20. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
